Alpha Fusion和Curadh中期审查伙伴开发Astatine-211放射性药剂,在全球扩大药物选择。 Alpha Fusion and Curadh MTR partner to develop Astatine-211 radiopharmaceuticals, expanding drug options globally.

Alpha Fusion, Inc.和Curadh Medic. Inc.建立了伙伴关系,在Astatine-211(At-211)的基础上开发放射药剂(At-211)。 Alpha Fusion, Inc. and Curadh MTR, Inc. have formed a partnership to develop radiopharmaceuticals based on Astatine-211 (At-211). 将Alpha Fusion在日本的药物发现工作与Curadh的发展专长结合起来,该合资企业将侧重于美国的临床发展,并在全球范围内扩大At-211产品管道。 Combining Alpha Fusion's drug discovery work in Japan with Curadh's development expertise, the joint venture will focus on clinical development in the US and expanding the pipeline of At-211 products globally. Alpha Fusion正在利用环子和GMP制造来加强其供应链,以支持这一增长。 Alpha Fusion is enhancing its supply chain using cyclotrons and GMP manufacturing to support this growth.